Peter Wijngaard PhD

Has more than 25 years of experience in the pharmaceutical industry and most recently was the Chief Development Officer at The Medicines Company leading the development of inclisiran before the company was acquired by Novartis in January 2020. Prior to The Medicines Company, I worked in various roles in Product Development, Medical Affairs, and Business Development in several large and small pharmaceutical companies. I led the global Transplantation Life Cycle Group, was the Global Alliance Director for Genentech at Hoffmann-La Roche and led the European Development and Medical Affairs teams at Viropharma. I started my career as a basic scientist in the Utrecht University Medical Center and am an author of more than 50 scientific articles on transplant immunology, immunosuppression and molecular biology. Has a PhD in Immunology from Utrecht University, the Netherlands.